{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:11:18Z","timestamp":1760235078560,"version":"build-2065373602"},"reference-count":19,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Endometrial cancer is the most common pelvic gynecological cancer in France. The most frequent symptom is post-menopausal bleeding and is one of the primary reasons for consultation in gynecological emergencies. The treatment is very codified and consists of a surgical intervention for anatomopathological analysis. The latter is frequently reassuring. These interventions are often performed in mild situations and there is currently no element to be sufficiently reassuring to avoid surgery. This study aims to explore the sensitivity of an innovative marker: Human Epididymis 4 (HE4) in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings. Methods: This is a prospective multicenter diagnostic study with three centers involved. Inclusion criteria are any patient with post-menopausal bleeding who is to undergo hysteroscopy, endometrial biopsy, or endometrial resection. In accordance with the recommendations for the management of post-menopausal bleedings, the medical conduct consists of performing a clinical examination, an ultrasound and, in general, even in case of paraclinical examination reassuring, an anatomopathological analysis. This pathological analysis can be obtained in several ways: biopsy, hysteroscopy-curettage (which is the most frequently performed surgery), and hysterectomy. Our protocol consists of taking a blood sample from each woman who will undergo one of the interventions mentioned above. The dosage of HE4 and CA125 requires the withdrawal of an additional heparinized tube during the preoperative assessment usually performed. This research is therefore classified as non-interventional. The primary outcome is to evaluate the sensitivity of the HE4 marker in patients with postmenopausal bleeding in the diagnosis of endometrial cancer. The secondary outcomes are other parameters (specificity, VPP, VPN) of HE4, Evaluating the diagnostic capabilities of the CA125 marker alone and associated with HE4, as well as those of the REM and REM-B algorithms. We aim to include 100 patients over a period of one year in three centers. Discussion: As of now, there is no biological marker used in routine practice in the diagnosis of endometrial cancer. The ultimate goal of HE4 in endometrial cancer is to avoid surgery for those who are identified as non-sick. This study is the precursor of others for use in routine practice, HE4 would represent a great help to diagnosis if our study demonstrates it as reliable in the management of these patients and avoid many unnecessary and risky surgeries.<\/jats:p>","DOI":"10.3390\/diagnostics11071274","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T23:28:30Z","timestamp":1626391710000},"page":"1274","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HE4 in the Diagnostic Approach of Endometrial Cancer in Patients with Postmenopausal Bleeding, the METRODEC Protocol: Protocol for a Multicenter Prospective Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Manon","family":"Degez","sequence":"first","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Caillon","sequence":"additional","affiliation":[{"name":"Service de Biochimie, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Chauvir\u00e9-Drouard","sequence":"additional","affiliation":[{"name":"Centre d\u2019Investigation Clinique CIC 1413, INSERM, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Leroy","sequence":"additional","affiliation":[{"name":"Plateforme de Biom\u00e9tries et Biostatistiques, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lair","sequence":"additional","affiliation":[{"name":"D\u00e9partement Promotion, Direction de la Recherche, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Winer","sequence":"additional","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CHU de Nantes, 44000 Nantes, France"},{"name":"Centre d\u2019Investigation Clinique CIC 1413, INSERM, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibault","family":"Thubert","sequence":"additional","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CHU de Nantes, 44000 Nantes, France"},{"name":"Centre d\u2019Investigation Clinique CIC 1413, INSERM, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Le Floch","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique, CH de Saint-Nazaire, 44600 Saint-Nazaire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Desroys du Roure","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Recherche Clinique, CH D\u00e9partemental Vend\u00e9e, 85000 La Roche sur Yon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Randet","sequence":"additional","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CH de Saint-Nazaire, 44600 Saint-Nazaire, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Ducarme","sequence":"additional","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CH D\u00e9partemental Vend\u00e9e, 85000 La Roche sur Yon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-0288","authenticated-orcid":false,"given":"Vincent","family":"Dochez","sequence":"additional","affiliation":[{"name":"Service de Gyn\u00e9cologie-Obst\u00e9trique, CHU de Nantes, 44000 Nantes, France"},{"name":"Centre d\u2019Investigation Clinique CIC 1413, INSERM, CHU de Nantes, 44000 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1055-9965.EPI-12-0996","article-title":"Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008","volume":"22","author":"Jamison","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ejca.2014.02.020","article-title":"Trends in corpus uteri cancer mortality in member states of the European Union","volume":"50","author":"Weiderpass","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_4","unstructured":"Defossez, G., Le Guyader-Peyrou, S., Uhry, Z., Grosclaude, P., Colonna, M., Dantony, E., Delafosse, P., Molini\u00e9, F., Woronoff, A.S., and Bouvier, A.M. (2019). Volume 1\u2013Tumeurs solides. Estimations Nationales de l\u2019incidence et de la Mortalit\u00e9 par Cancer en France M\u00e9tropolitaine Entre 1990 et 2018, Sant\u00e9 publique. Available online: http:\/\/www.santepubliquefrance.fr\/."},{"key":"ref_5","unstructured":"Institut National Du Cancer (2020, May 19). Cancer De L\u2019endom\u00e8tre: Synth\u00e8se Des Recommandations. [Internet]. Available online: https:\/\/www.e-cancer.fr."},{"key":"ref_6","first-page":"474","article-title":"Management of side effects under hormonal replacement therapy in menopausal women: Abnormal uterine bleeding. Postmenopausal women management: CNGOF and GEMVi clinical practice guidelines","volume":"49","author":"Hamdaoui","year":"2021","journal-title":"Gynecol. Obs. Fertil. Senol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jamainternmed.2018.2820","article-title":"Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women: A Systematic Review and Meta-analysis","volume":"178","author":"Clarke","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_9","unstructured":"Institut National Du Cancer (2019, June 12). Conduites \u00e0 Tenir Initiales Devant Des Patientes Atteintes d\u2019un Cancer \u00c9pith\u00e9lial De l\u2019ovaire. Synth\u00e8se, Novembre 2018; [Internet]. Available online: https:\/\/www.e-cancer.fr."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dochez, V., Randet, M., Renaudeau, C., Dimet, J., Le Thuaut, A., Winer, N., Thubert, T., Vaucel, E., Caillon, H., and Ducarme, G. (2019). Efficacy of HE4, CA125, Risk of Malignancy Index and Risk of Ovarian Malignancy Index to Detect Ovarian Cancer in Women with Presumed Benign Ovarian Tumours: A Prospective, Multicentre Trial. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111784"},{"key":"ref_11","first-page":"468","article-title":"Diagnosis and Management of Endometrial Cancer","volume":"93","author":"Braun","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15296\/ijwhr.2020.14","article-title":"The Utility of CA125 and HE4 in Patients Suffering From Endometrial Cancer","volume":"8","author":"Zamani","year":"2019","journal-title":"Int. J. Women\u2019s Health Reprod. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s13277-013-1190-4","article-title":"A Critical Review on HE4 Performance in Endometrial Cancer: Where Are We Now?","volume":"35","author":"Angioli","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2018.11.011","article-title":"Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis","volume":"488","author":"Li","year":"2019","journal-title":"Clin. Chim. Acta Janv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/01443615.2016.1174199","article-title":"The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions","volume":"37","author":"Kerimoglu","year":"2017","journal-title":"J. Obs. Gynaecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2020.12.029","article-title":"Endometrial cancer: A systematic review of HE4, REM and REM-B","volume":"515","author":"Degez","year":"2021","journal-title":"Clin. Chim. Acta. Avr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14737159.2016.1251317","article-title":"Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies","volume":"16","author":"Qu","year":"2016","journal-title":"Expert. Rev. Mol. Diagn."},{"key":"ref_18","first-page":"XC01","article-title":"Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study","volume":"11","author":"Dewan","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/aogs.12235","article-title":"HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: A prospective multicenter study (ENDOMET)","volume":"92","author":"Antonsen","year":"2013","journal-title":"Acta Obs. Gynecol. Scand."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/7\/1274\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:17Z","timestamp":1760164277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/7\/1274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["diagnostics11071274"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11071274","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}